First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis-MedSci.cn

First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis

Peng, Y; Zeng, XH; Peng, LB; Liu, Q; Yi, LD; Luo, X; Li, SN; Wang, LT; Qin, SX; Wan, XM; Tan, CQ

Wan, XM; Tan, CQ (corresponding author), Cent South Univ, Dept Pharm, Second Xiangya Hosp, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.

ADVANCES IN THERAPY, 2021; 38 (5): 2447

Abstract

Introduction The IMpower110 trial evaluated the efficacy and safety of atezolizumab in previously untreated patients with metastatic non-small cell lu......

Full Text Link